A Minireview on the Morpholine-Ring-Containing U.S. FDA Approved Drugs: A Medicinal-Chemistry-Based Analysis from 2013 to 2023
Synlett · 2025-10 · 36 (16) · 2527-2536
DOI: 10.1055/a-2547-8990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synlett, online erschienen am 22.04.2025. Verfasst von Sarthak Puri und 8 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Heterocyclic scaffolds, especially oxazines, constitute a significant component of clinically pertinent pharmaceuticals. Morpholine enhances the solubility, bioavailability, and metabolic stability of drug molecules because of its structural feature that gives optimum basicity (pK a = ca. 8.7), hydrogen bonding, and an electron-deficient ring system. Apart from structural features, incorporating morpholine ring systems in drug molecules improved their pharmacokinetic profiles also. It provides optimum lipid solubility as well as aqueous solubility. As a bioisosteric replacement unit for piperazine, piperidine, etc., the morpholine ring provides optimum basicity and lipophilicity. We have examined U.S. FDA approved small-molecule drugs (2012–2023) incorporating morpholine as core ring structures. The analysis identified 14 drugs approved in the past decade that contain morpholine ring systems, with 50% classified as anticancer agents. The CYP3A4 enzyme was identified as the main driver for the metabolism of these drugs, with the majority being excreted via feces. Three morpholine-containing drugs were identified as possessing chiral centers, taking into account stereochemical aspects. In addition to covering drugs with morpholine rings, the perspective offers a comprehensive analysis utilizing molecular descriptors, chemical space parameters, and commentary on these medications’ pharmacokinetic and pharmacodynamic aspects. This enhances the article’s medicinal chemistry dimension and renders it a valuable resource for the medicinal and allied science community. 1 Introduction 2 Insights towards the Chemistry of Morpholine 3 Synthetic Strategies to Develop Morpholine Derivatives 4 Implication of Morpholine in Improvising the Pharmacokinetics and Efficacy of Pharmaceutical Drugs: Case Studies 5 Comparative Analysis of the Pharmacological Class of the Approved Drugs Possessing Morpholine System 6 Delving Deeper into the Approved Drugs Bearing the Morpholine-Based Core Systems 7 Analysis and Conclusion 8 Summary
Zitieren
APA
Puri, S., Goel, K. K., Singhal, P., Sathish, E., Babu, M. A., Pandey, S. K., Tyagi, Y., Kumar, R., & Singh, T. G. (2025). A Minireview on the Morpholine-Ring-Containing U.S. FDA Approved Drugs: A Medicinal-Chemistry-Based Analysis from 2013 to 2023. Synlett, 36(16), 2527-2536. https://doi.org/10.1055/a-2547-8990
Vancouver
Puri S, Goel KK, Singhal P, Sathish E, Babu MA, Pandey SK, et al. A Minireview on the Morpholine-Ring-Containing U.S. FDA Approved Drugs: A Medicinal-Chemistry-Based Analysis from 2013 to 2023. Synlett. 2025;36(16):2527-2536. doi:10.1055/a-2547-8990
BibTeX
@article{Puri2025,
author = {Puri, Sarthak and Goel, Kapil Kumar and Singhal, Peeush and Sathish, Elagandhula and Babu, M. Arockia and Pandey, Sarvesh Kumar and Tyagi, Yogita and Kumar, Roshan and Singh, Thakur Gurjeet},
title = {A Minireview on the Morpholine-Ring-Containing U.S. FDA Approved Drugs: A Medicinal-Chemistry-Based Analysis from 2013 to 2023},
journal = {Synlett},
year = {2025},
volume = {36},
number = {16},
pages = {2527--2536},
doi = {10.1055/a-2547-8990}
}
EUVIMED